Jul 19, 2024
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
May 14, 2024
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
Jan 28, 2021
CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients
Dec 23, 2020
CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation
Dec 16, 2020
CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer
Nov 18, 2020
CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T)
Nov 09, 2020
CASI Pharmaceuticals Announces Third Quarter 2020 Financial Results
Nov 05, 2020
CASI Pharmaceuticals To Report Third Quarter 2020 Financial Results And Host Conference Call November 9, 2020
Sep 29, 2020
CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd
Sep 11, 2020
CASI Pharmaceuticals, Inc. to Participate in Two Upcoming September Conferences
Aug 10, 2020
CASI Pharmaceuticals Announces Second Quarter 2020 Financial Results
Aug 03, 2020
CASI Pharmaceuticals To Report Second Quarter 2020 Financial Results And Host Conference Call August 10, 2020
Jul 21, 2020
CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Jun 08, 2020
CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program
Jun 02, 2020
CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference
May 11, 2020
CASI Pharmaceuticals Announces First Quarter 2020 Financial Results
Apr 07, 2020
CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor Conference
Dec 03, 2019
CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications
Nov 07, 2019
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly
Sep 19, 2019
CASI Pharmaceuticals Announces The Promotion Of Larry Zhang To President